Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).
Chehrazi-Raffle A, Tukachinsky H, Schrock A, Hwang J, Zengin Z, Meza L, Chawla N, Ebrahimi H, Govindarajan A, Castro D, Rock A, Tripathi A, Dorff T, Pal S, Oxnard G, Agarwal N, Antonarakis E. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC). Journal Of Clinical Oncology 2023, 41: 220-220. DOI: 10.1200/jco.2023.41.6_suppl.220.Peer-Reviewed Original ResearchAdvanced prostate cancerComprehensive genomic profilingGenomic alterationsBRAF alterationsTissue biopsiesCancer typesFurther clinical investigationTMPRSS2-ERG fusionFoundationOne CDxMedian ageCommon genomic alterationsAPC patientsProstate cancerMolecular subtypesClinical investigationHigh incidenceActionable targetsBRAF rearrangementsCancer-related genesHotspot missense mutationsGenomic profilingBRAFCDK12 mutationsGenetic activationBiopsy